Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camurus AB's Total Assets for the quarter that ended in Jun. 2026 was kr5,306 Mil.
During the past 12 months, Camurus AB's average Total Assets Growth Rate was 15.00% per year.
During the past 3 years, the average Total Assets Growth Rate was 11.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 11.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 27.30% per year.
During the past 13 years, Camurus AB's highest 3-Year average Total Assets Growth Rate was 53.40%. The lowest was -8.00%. And the median was 20.90%.
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Camurus AB's Asset Turnover for the quarter that ended in Jun. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Camurus AB Total Assets Related Terms
Camurus AB Total Assets Historical Data
* Premium members only.
The historical data trend for Camurus AB's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Camurus AB's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (OSTO:CAMX) has a Total Assets of kr5,306 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Camurus AB and its competitors.
Is Camurus AB's Total Assets too high?
Camurus AB's current Total Assets is kr5,306 Mil. Overall, Camurus AB has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Total Assets compare to VRTX and REGN?
Camurus AB's Total Assets of kr5,306 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Camurus AB and its competitors. Camurus AB's current Total Assets is kr5,306 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (OSTO:CAMX) is currently considered Fairly Valued. The stock's GF Value™ is kr677.94, compared to a current price of kr619.00 — trading 8.7% below its estimated fair value. The current Total Assets is kr5,306 Mil. Camurus AB's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Camurus AB (OSTO:CAMX), the current Total Assets is kr5,306 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (OSTO:CAMX) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of kr619.00 is trading 8.7% below its estimated GF Value™ of kr677.94.
GuruFocus considers Camurus AB to be Fairly Valued.
Key valuation signals for OSTO:CAMX:
Total Assets: kr5,306 Mil
GF Value™: kr677.94 vs. price of kr619.00 (8.7% below fair value)
No single metric tells the full story. See the OSTO:CAMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
82GF Score
Get the complete analysis for OSTO:CAMX
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:CAMX has been successfully added to your 
